ALXO_OUT_1 [2025-04-14 15:54:32 -0400] 3098 Bytes | 821 tokens | Cum: 821 tkns (10.26% of 8k)
==========================================================================

Listen up, partner—it's 3:54:31 PM on Mon Apr 14, 2025 -0400, and I’m revved up about ALX Oncology (ALXO), climbing from 0.4900 to 0.5053. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: ALX Oncology (ALXO)
IPO: 2020-07-17 (4 Years Ago)
Market Cap: $27,145,838
Shares Outstanding: 53,380,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Here’s the first list of news for ALX Oncology:

C1 - Apr-07-25 08:00AM - ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
C2 - Mar-20-25 09:55AM - ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
C3 - Mar-08-25 07:33AM - Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
C4 - Mar-07-25 01:27PM - Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday
C5 - Mar-06-25 04:01PM - ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
C6 - Mar-05-25 08:00AM - ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
C7 - Feb-27-25 08:00AM - ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
C8 - Feb-18-25 08:00AM - ALX Oncology to Host Virtual R&D Day on March 5, 2025

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and report parser.
Your role is to examine all available company data and draw sound conclusions.
The company under analysis is: ALX Oncology (ALXO).

2) To request information, refer to any listed documents using their reference codes.

3) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:

Restrict all your responses to just 3 tokes until it's time for the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

ALXO_OUT_3 [2025-04-14 15:54:33 -0400] 251 Bytes | 78 tokens | Cum: 902 tkns (11.28% of 8k)
==========================================================================

You just read a chunk of A1.
You may now:
- Say "MOR" to continue this article
- Say "A2", "A3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 3 articles from this list. If you’re ready to move on, say NEX.

ALXO_OUT_5 [2025-04-14 15:54:34 -0400] 978 Bytes | 310 tokens | Cum: 1215 tkns (15.19% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-10T14:55:23Z - ALXO stock plunges to 52-week low of $0.48 amid market challenges By Investing.com...
A2 - 2025-04-07T13:23:38Z - ALX Oncology gets FDA clearance to begin trial of ALX2004...
A3 - 2025-04-07T12:32:45Z - ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug ...
A4 - 2025-04-07T12:23:36Z - ALX Oncology (ALXO) Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody...
A5 - 2025-04-07T12:13:25Z - ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug C...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ALXO_OUT_7 [2025-04-14 15:54:34 -0400] 1098 Bytes | 307 tokens | Cum: 1524 tkns (19.05% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**ALXO stock plunges to 52-week low of $0.48 amid market challenges By Investing.com**Date: 2025-04-10Source: {'uri': 'investing.com', 'dataType': 'news', 'title': 'Investing.com'}URL: https://www.investing.com/news/company-news/alxo-stock-plunges-to-52week-low-of-048-amid-market-challenges-93CH-3979723In a stark reflection of the volatile market conditions, Alx Oncology Holdings Inc. (ALXO) stock has tumbled to a 52-week low of $0.48, with the current price at $0.49. According to InvestingPro analysis, the stock is trading below its Fair Value, with analyst price targets ranging from $1.50 to $5.00. This significant downturn has reduced the company's market capitalization to just $26.69 million, with the stock declining by 95.7% over the past year. Investors have been closely monitoring ALXO as it navigates through a challenging phase, marked by investor skepticism and broader marke

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALXO_OUT_9 [2025-04-14 15:54:38 -0400] 1098 Bytes | 255 tokens | Cum: 1781 tkns (22.26% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): t headwinds that have pressured the biotechnology sector. InvestingPro data reveals a weak overall financial health score, though the company maintains a strong current ratio of 7.26. The 52-week low serves as a critical indicator of the hurdles the company faces, as it struggles to regain its footing in a competitive and rapidly evolving industry landscape. The stock's Price/Book ratio of 0.24 reflects the market's current pessimistic outlook on the company's prospects.

In other recent news, ALX Oncology has announced the U.S. Food and Drug Administration (FDA) clearance for an Investigational New Drug application for ALX2004, aimed at treating solid tumors expressing the epidermal growth factor receptor. The company plans to initiate Phase 1 clinical trials in mid-2025. In addition, ALX Oncology has disclosed a strategic workforce reduction of approximately 30% to prioritize its produ

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALXO_OUT_11 [2025-04-14 15:54:40 -0400] 1026 Bytes | 246 tokens | Cum: 2076 tkns (25.95% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): ct pipeline and conserve cash, with completion expected by May 2025. The departure of President and Chief Scientific Officer, Dr. Jaume Pons, is part of this reorganization.

Analyst opinions on ALX Oncology have varied recently. Stifel has reduced its price target to $1.50 while maintaining a Hold rating, citing concerns over development strategies and regulatory risks. Meanwhile, Jefferies has upgraded the stock to Buy, raising the price target to $3.00, based on a favorable risk/reward assessment. UBS has also adjusted its price target to $2.20, down from $4.00, but retains a Buy rating, noting the need for further investigation into the efficacy of evorpacept in HER2-positive gastric cancer. These developments reflect the ongoing strategic adjustments and varied analyst perspectives on ALX Oncology's prospects.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALXO_OUT_13 [2025-04-14 15:54:41 -0400] 1218 Bytes | 360 tokens | Cum: 2470 tkns (30.88% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-08T12:33:00Z - Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
B2 - 2024-12-18T13:00:00Z - ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
B3 - 2024-11-01T21:30:00Z - ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
B4 - 2024-10-01T17:00:00Z - Breast Cancer Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
B5 - 2024-07-24T08:02:00Z - EnerVenue Names Steffen Pietzke as Chief Financial Officer - GlobeNewswire
B6 - 2024-07-03T18:30:04Z - Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALXO_OUT_15 [2025-04-14 15:54:44 -0400] 704 Bytes | 196 tokens | Cum: 2668 tkns (33.35% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/25/03/n44208923/why-the-global-cancer-market-could-surpass-900-billion-and-the-stocks-leading-the-chargeThe global cancer market is projected to surpass $900 billion by 2034, driven by advancements in cancer treatments from biotech companies like Oncolytics Biotech, Exelixis, Cardiff Oncology, ALX Oncology, and Verastem.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALXO_OUT_17 [2025-04-14 15:54:45 -0400] 797 Bytes | 196 tokens | Cum: 2946 tkns (36.83% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S3 - 2025-03-06 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion of our financial condition and results of operations together with our CONS financial statements and related notes included elsewhere ...

S4 - 2025-03-06 8-K Item 2.02Results of Oper and Fin Cond.

On March 6, 2025, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2024. A copy of this press release is furnished ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ALXO_OUT_19 [2025-04-14 15:54:46 -0400] 1098 Bytes | 257 tokens | Cum: 3205 tkns (40.06% of 8k)
==========================================================================

Showing S3 (chunk 1 of 6): S3:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and analysis generally addresses 2024 and 2023 items and year-over-year comparisons between 2024 and 2023. Discussions of 2022 items and year-over-year comparisons between 2023 and 2022 that are not included in this Annual Report on Form 10-K can be found in Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 7, 2024. Some of the information contained in this discussion and analysis, including information with res

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALXO_OUT_21 [2025-04-14 15:54:48 -0400] 1098 Bytes | 250 tokens | Cum: 3457 tkns (43.21% of 8k)
==========================================================================

Showing S3 (chunk 2 of 6): pect to our plans and strategy for our business, include forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Risk Factors and elsewhere in this Annual Report on Form 10-K.

Overview

We are a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint and bridge the innate and adaptive immune system. Our lead product candidate, the CD47 blocker evorpacept, is currently in multiple Phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a dont eat me signal to evade macrophage phagocytosis or as a dont activate T-cells signal that prevents activation of T-cells by dendritic cells. We are developing ev

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALXO_OUT_23 [2025-04-14 15:54:48 -0400] 1098 Bytes | 255 tokens | Cum: 3714 tkns (46.42% of 8k)
==========================================================================

Showing S3 (chunk 3 of 6): orpacept to be a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Evorpacept is a next-generation CD47 blocking therapeutic that we believe has significantly enhanced properties compared to competing CD47 blocking approaches. Evorpacept is a fusion protein that combines a high-affinity CD47 binding domain with a proprietary inactivated Fc domain. The CD47 binding domain of evorpacept is an affinity enhanced extracellular domain of SIRP, a protein that is the natural receptor to CD47 found on myeloid cells. We have engineered the Fc domain of evorpacept so that it does not provide a pro-phagocytic signal while still maintaining an antibody-like half-life for the molecule. We believe our inactive Fc approach improves tolerability when compared to other C

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ALXO_OUT_25 [2025-04-14 15:54:58 -0400] 7107 Bytes | 1976 tokens | Cum: 5692 tkns (71.15% of 8k)
==========================================================================

This is our set of metrics for ALX Oncology.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+----------------------+
| Volume: 331,714 | Perf Month: -39.10% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 1.01M | Perf Quarter: -70.09% | Short Float: 18.52% | ROE: -88.91% |
+-------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 0.35 | Index: RUT | Short Ratio: 6.26 | ROI: -105.15% |
+-------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 30.97 | Market Cap: 26.98M | Short Interest: 6.30M | Sales Surprise: - |
+-------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.08 | Shs Outstand: 53.05M | Beta: 1.25 | EPS Surprise: 17.91% |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA20: -18.07% | Shs Float: 33.99M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA50: -43.18% | Inst Own: 56.29% | Sales past 5Y: -35.07% | Earnings: Mar 06 AMC |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA200: -76.24% | Insider Own: 36.33% | Employees: 80 | |
+-------------------+-----------------------+-------------------------+----------------------+
| Perf Week: -5.57% | Insider Trans: 0.06% | Debt/Eq: 0.15 | |
+-------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading by ALX Oncology officers or majority shareholders (if available).

Inside Trans: ALX ONCOLOGY HOLDINGS INC (ALXO) by Lettmann Jason (CHIEF EXECUTIVE OFFICER) on 2025-03-14
- Common Stock: 42000 shares at $0 (D)

Inside Trans: ALX ONCOLOGY HOLDINGS INC (ALXO) by Pinto Shelly (SVP, FINANCE AND CAO) on 2025-03-14
- Common Stock: 3000 shares at $0 (D)

Inside Trans: ALX ONCOLOGY HOLDINGS INC (ALXO) by Lettmann Jason (CHIEF EXECUTIVE OFFICER) on 2025-02-19
- Common Stock: 2159 shares at $1.1502 (D) Footnote: The shares were sold to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units.

Inside Trans: ALX ONCOLOGY HOLDINGS INC (ALXO) by Pons Jaume (PRESIDENT & CSO) on 2025-02-19
- Common Stock: 1326 shares at $1.1502 (D) Footnote: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

Inside Trans: ALX ONCOLOGY HOLDINGS INC (ALXO) by Pinto Shelly (SVP, FINANCE AND CAO) on 2025-02-19
- Common Stock: 550 shares at $1.1502 (D) Footnote: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.

No transactions recorded.

Inside Trans: ALX ONCOLOGY HOLDINGS INC (ALXO) by Takimoto Chris H (Unknown Title) on 2025-01-21
- Common Stock (right to buy): 40400 shares at $0 (D)

Inside Trans: ALX ONCOLOGY HOLDINGS INC (ALXO) by GOODMAN COREY S (Unknown Title) on 2025-01-21
- Stock Option (right to buy): 40400 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -134850000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.5053
Average Volume: 518607.0
30-Day High: 0.7836
30-Day Low: 0.48

[Detailed Financials: TTM 2024]
- Total Assets: $147,775,000.0
- Total Liabilities: $34,157,000.0
- Total Equity: $113,618,000.0
- Current Assets: $134,352,000.0
- Current Liabilities: $18,500,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.58

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-4,839,000.0

[Detailed Financials: FY 2024]
- Total Assets: $147,775,000.0
- Total Liabilities: $34,157,000.0
- Total Equity: $113,618,000.0
- Current Assets: $134,352,000.0
- Current Liabilities: $18,500,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.58

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-4,839,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of ALX Oncology (ALXO).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about ALX Oncology.

2) MARKET_SCORE[]
This conversation was initiated because ALXO is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ALXO.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ALXO could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ALXO to increase 50% from its current price of $0.51, say: PRICE_TARGET[0.76]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of ALX Oncology.

11) ETHICAL_RATING[]
Rate ALX Oncology’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ALXO_IN_27 [2025-04-14 15:54:58 -0400] 126 Bytes | 29 tokens | Cum: 5917 tkns (73.96% of 8k)
==========================================================================

====================================
[2025-04-14 15:54:58] # Analysis Completed
Elapsed Time: 26.73 seconds